Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT T MORRIS

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1659342756
CMS profile
119658
Location
DETROIT, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$90,372.23

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT T MORRIS

NPI 1659342756 · CMS profile ID 119658

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

DETROIT, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659342756?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT T MORRIS, NPI 1659342756, CMS profile ID 119658. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659342756?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ROBERT T MORRIS, NPI 1659342756, CMS profile ID 119658. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659342756?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ROBERT T MORRIS, NPI 1659342756, CMS profile ID 119658, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1659342756?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $90,372.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–67 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $2,740.0005/13/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834353655 CMS
GlaxoSmithKline, LLC. $4,800.0004/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802801631 CMS
GlaxoSmithKline, LLC. $15.5604/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801605832 CMS
GlaxoSmithKline, LLC. $1,200.0004/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 860859955 CMS
Roche Diagnostics Corporation $5,280.0004/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844261333 CMS
GlaxoSmithKline, LLC. $4.1604/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802924875 CMS
GlaxoSmithKline, LLC. $716.1003/25/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802287843 CMS
GlaxoSmithKline, LLC. $110.5303/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802523219 CMS
AstraZeneca Pharmaceuticals LP $1,350.0003/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834344845 CMS
AstraZeneca Pharmaceuticals LP $20.0103/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834324493 CMS
Aspira Women's Health Inc $50.0002/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783105245 CMS
Clovis Oncology, Inc. $85.6602/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 790253577 CMS
Clovis Oncology, Inc. $115.8902/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 790255867 CMS
Merck Sharp & Dohme Corporation $15.5502/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848679523 CMS
Aspira Women's Health Inc $50.0001/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783105241 CMS
Clovis Oncology, Inc. $19.4701/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 790253323 CMS
Clovis Oncology, Inc. $24.8101/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 790253315 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $105,240.86 120
PY2020 $59,911.38 51
PY2021 $90,372.23 67
PY2022 $108,377.30 83
PY2023 $180,361.62 154
PY2024 $151,029.55 129
PY2025 $111,305.45 122

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $253,422.98 64
PY2024 Principal investigator $20,176.77 5
PY2023 Principal investigator $143,274.76 17
PY2022 Principal investigator $57,820.38 15
PY2021 Principal investigator $152,481.04 31
PY2020 Principal investigator $164,358.09 43
PY2019 Principal investigator $1,306,294.58 94

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genmab U.S., Inc. $14,036.50 12/16/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235924454
Principal investigator 1 GlaxoSmithKline, LLC. $297.50 12/04/2025 Non-covered Recipient Entity
KARMANOS CANCER CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB No dispute reported 06/30/2026 1192177027
Principal investigator 1 ABBVIE INC. $4,000.00 11/24/2025 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine No dispute reported 06/30/2026 1202413675
Principal investigator 1 Genmab U.S., Inc. $201.50 11/20/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235924450
Principal investigator 1 Genmab U.S., Inc. $92.52 11/20/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235924461
Principal investigator 1 Genmab U.S., Inc. $780.00 11/20/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235924465
Principal investigator 1 pharmaand GmbH $811.20 11/20/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 1182992191
Principal investigator 1 Genmab U.S., Inc. $910.00 11/13/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235924442
Principal investigator 1 Genmab U.S., Inc. $938.60 11/13/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235924446
Principal investigator 1 Genmab U.S., Inc. $6,440.45 11/13/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235924458
Principal investigator 1 Karyopharm Therapeutics Inc. $4,069.80 11/13/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662778
Principal investigator 1 AstraZeneca UK Limited $4,842.40 10/22/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
ROSY-O Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment No dispute reported 06/30/2026 1185550375
Principal investigator 1 ABBVIE INC. $2,000.00 10/02/2025 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine No dispute reported 06/30/2026 1202413636
Principal investigator 1 pharmaand GmbH $1,282.50 09/25/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 1182992189
Principal investigator 1 GlaxoSmithKline, LLC. $5,185.70 09/23/2025 Non-covered Recipient Entity
KARMANOS CANCER CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB No dispute reported 06/30/2026 1192179389
Principal investigator 1 Karyopharm Therapeutics Inc. $411.00 09/16/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662776
Principal investigator 1 Karyopharm Therapeutics Inc. $411.00 09/16/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662790
Principal investigator 1 Karyopharm Therapeutics Inc. $1,277.64 08/27/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662742
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 08/27/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662748
Principal investigator 1 Karyopharm Therapeutics Inc. $1,534.68 08/27/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662782
Principal investigator 1 Iovance Biotherapeutics, Inc. $6,252.00 08/14/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
131462 No dispute reported 06/30/2026 1252498025
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,334.00 08/01/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
131462 No dispute reported 06/30/2026 1252498023
Principal investigator 1 Karyopharm Therapeutics Inc. $240.66 07/29/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662756
Principal investigator 1 ABBVIE INC. $40,540.00 07/09/2025 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine No dispute reported 06/30/2026 1202413604
Principal investigator 1 pharmaand GmbH $1,282.50 06/18/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 1182992185
Principal investigator 1 pharmaand GmbH $2,717.00 06/18/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 1182992187
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,500.00 06/13/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
NCT03108495 No dispute reported 06/30/2026 1252496619
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,547.60 06/13/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
NCT03108495 No dispute reported 06/30/2026 1252496621
Principal investigator 1 Iovance Biotherapeutics, Inc. $10,591.05 06/13/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
NCT03108495 No dispute reported 06/30/2026 1252496623
Principal investigator 1 Karyopharm Therapeutics Inc. $246.96 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662734
Principal investigator 1 Karyopharm Therapeutics Inc. $240.66 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662738
Principal investigator 1 Karyopharm Therapeutics Inc. $3,664.08 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662740
Principal investigator 1 Karyopharm Therapeutics Inc. $246.96 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662746
Principal investigator 1 Karyopharm Therapeutics Inc. $1,155.42 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662750
Principal investigator 1 Karyopharm Therapeutics Inc. $491.10 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662752
Principal investigator 1 Karyopharm Therapeutics Inc. $4,069.80 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662758
Principal investigator 1 Karyopharm Therapeutics Inc. $4,799.72 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662760
Principal investigator 1 Karyopharm Therapeutics Inc. $177.66 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662762
Principal investigator 1 Karyopharm Therapeutics Inc. $1,181.88 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662766
Principal investigator 1 Karyopharm Therapeutics Inc. $1,449.00 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662768
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662772
Principal investigator 1 Karyopharm Therapeutics Inc. $1,449.00 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662774
Principal investigator 1 Karyopharm Therapeutics Inc. $1,181.88 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662780
Principal investigator 1 Karyopharm Therapeutics Inc. $240.66 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662784
Principal investigator 1 Karyopharm Therapeutics Inc. $246.96 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662786
Principal investigator 1 Karyopharm Therapeutics Inc. $246.96 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662792
Principal investigator 1 Karyopharm Therapeutics Inc. $1,155.42 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662796
Principal investigator 1 Karyopharm Therapeutics Inc. $128.50 05/28/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662798
Principal investigator 1 Iovance Biotherapeutics, Inc. $37,000.00 04/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
131462 No dispute reported 06/30/2026 1252496625
Principal investigator 1 Iovance Biotherapeutics, Inc. $6,000.00 04/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
131462 No dispute reported 06/30/2026 1252496627
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,040.00 04/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
131462 No dispute reported 06/30/2026 1252496629
Principal investigator 1 GlaxoSmithKline, LLC. $892.50 04/21/2025 Non-covered Recipient Entity
KARMANOS CANCER CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB No dispute reported 06/30/2026 1192177022
Principal investigator 1 Genmab U.S., Inc. $35,000.00 04/16/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235924037
Principal investigator 1 pharmaand GmbH $4,702.50 04/14/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 1182992183
Principal investigator 1 Karyopharm Therapeutics Inc. $2,056.32 03/03/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662754
Principal investigator 1 Karyopharm Therapeutics Inc. $2,056.32 03/03/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662764
Principal investigator 1 Karyopharm Therapeutics Inc. $3,997.98 02/26/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662736
Principal investigator 1 Karyopharm Therapeutics Inc. $630.00 02/26/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662744
Principal investigator 1 Karyopharm Therapeutics Inc. $3,997.98 02/26/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662788
Principal investigator 1 Karyopharm Therapeutics Inc. $630.00 01/27/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662794
Principal investigator 1 Adaptimmune LLC $1,236.00 01/23/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
SURPASS 3 No dispute reported 06/30/2026 1248275107
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,500.00 01/23/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
NCT03108495 No dispute reported 06/30/2026 1252496615
Principal investigator 1 Karyopharm Therapeutics Inc. $2,056.32 01/23/2025 Non-covered Recipient Entity
Barbara Ann Karmanos Cancer Institute
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662770
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,000.00 01/16/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
NCT03108495 No dispute reported 06/30/2026 1252496617